Becton, Dickinson and Company $BDX Shares Bought by IFP Advisors Inc

IFP Advisors Inc lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 17.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,452 shares of the medical instruments supplier’s stock after acquiring an additional 973 shares during the period. IFP Advisors Inc’s holdings in Becton, Dickinson and Company were worth $1,112,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company during the 1st quarter valued at $26,000. Smallwood Wealth Investment Management LLC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth about $27,000. Alpine Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC lifted its position in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares during the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $31,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 in the last ninety days. Insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent analyst reports. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 price target on the stock. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $186.41 on Monday. The company has a market capitalization of $53.43 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 1.46 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a 50-day moving average of $190.07 and a 200-day moving average of $185.73. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.